Pharmalink planning IPO next year, raises $12 million to fund research for lead product

1 October 2015

Sweden-based specialty pharma company Pharmalink on Thursday said it is planning an initial public offering on Nasdaq Stockholm in 2016 to fund the development of its lead drug candidate to treat a kidney disease and that it has raised 100 million Swedish kronor ($12 million) from its investors to advance its research for its Nefecon (PL-56).

The funds from the investor raising will be used to prepare a Phase III clinical trial for its drug candidate Nefecon. The condition progresses to end-stage renal disease in up to 40% patients.

The Phase II trial of Nefecon in 150 patients met its primary efficacy endpoint. Final results from the trial are expected in the fourth quarter 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK